Bereiche

Schlagwörter (Tags)

Kontakt

---

Zitation

Art

Zeitschrift

Veröffentlichungsdatum

Seiten

Kurzbeschreibung/Zielsetzung

Based on results from randomized phase III studies adjuvant cisplatin-based chemotherapy represents the current standard of care in
patients with resected stage IB-III non-small cell lung cancer. A pooled analysis of the five largest cisplatin-based adjuvant chemotherapy
trials conducted after 1995 showed an absolute overall survival benefit of 5.4% at five years. Even though almost 50 % of non-small cell lung
cancers occur in patients older than 70, this group of patients were under-represented in these studies with less than 10 % falling into this
category. We herein review the studies which investigated this subgroup of patients.